公开(公告)号：EP2203181A4

公开(公告)日：2013-01-16

申请号：EP08840520

申请日：2008-10-16

申请人： BIOCON LTD

发明人： KHEDKAR ANAND ,  RANGAPPA SHARATH KUMAR MALLAPURA ,  SUBRAMANI RAMESH ,  DAVE NITESH ,  RADHAKRISHNAN DEVESH ,  SHANKAR SUNDARESH ,  CHIVUKULA SUDHEER ,  RAMAKRISHNA RANJITH ,  MURTHY SHANMUGAM THANDAVA ,  PAI HARISH VENKATRAMAN ,  SENGUPTA NILANJAN ,  MELARKODE RAMAKRISHNAN ,  IYER HARISH

IPC分类号： A61K9/20 ,  A61K9/16 ,  A61K38/28 ,  A61K47/48

CPC分类号： A61K9/2077 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K38/28 ,  A61K47/542 ,  A61K47/543

摘要： The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations.

公开(公告)号：EP3024922A4

公开(公告)日：2017-03-29

申请号：EP14830053

申请日：2014-07-23

申请人： BIOCON LTD ,  CENTRO DE INMUNOLGÍA MOLECULAR

发明人： NAIR PRADIP ,  MELARKODE RAMAKRISHNAN ,  VENKATARAMAN RASIKA ,  ADHIKARY LAXMI ,  BHATNAGAR ANKUR ,  PRABHU SUNAINA ,  SHUKLA KRITI ,  BASKAR DINESH ,  DESAN SARAVANAN ,  PAI HARISH VENKATRAMAN ,  MONTERO CASIMIRO JOSE ENRIQUE

IPC分类号： C12N1/00 ,  A61K39/00 ,  C07K14/00 ,  C07K16/00 ,  C07K16/28 ,  C12N5/00 ,  C12P21/00

CPC分类号： C12P21/005 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92 ,  C07K2319/30

摘要： The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.

摘要翻译： 本发明涉及用于控制，抑制或减少真核生物和/或真核蛋白表达系统中的蛋白质岩藻糖基化的方法或方法。 所述方法包括在锰或锰离子的总浓度升高的情况下进行蛋白质表达和/或翻译后修饰。